BofA raised the firm’s price target on GSK (GSK) to 2,350 GBp from 2,100 GBp and keeps a Neutral rating on the shares. After having surveyed 20 U.S. academic and community hematologists and oncologists to assess potential uptake of Blenrep, the firm says its doc feedback on penetration underpins BofA’s un-risk adjusted GBP 2.2B peak sales estimates and offers “material upside” to consensus at GBP 1.1B.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK price target raised to $70 from $55 at TD Cowen
- Balancing Blenrep Upside With Valuation and Execution Risks: Why the Risk‑Reward Remains a Hold
- Balancing Strategic Promise and Execution Risk: Justifying a Hold Rating on GSK
- GSK Earnings Call: Specialty Strength Amid Vaccine Drags
- Trump Trade: Argentina says U.S. to cut hundreds of tariffs